Wave Life Sciences Ltd - Company Profile
Powered by 
All the sales intelligence you need on Wave Life Sciences Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Wave Life Sciences Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Wave Life Sciences Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Wave Life Sciences Ltd (Wave Life Sciences) discovers, develops, and commercializes medicines for genetic diseases. The company's pipeline include WVE-006 for the treatment of antitrypsin deficiency (AATD); WVE-007 targets obesity and other metabolic disorders; WVE-N531 treats Duchenne muscular dystrophy (DMD); WVE-003 is for Huntington's disease (HD). The company employs its proprietary chemistry platform PRISM, to design, optimize and manufacture stereo pure oligonucleotides with improved safety, tolerability and efficacy compared to that of stereorandom oligonucleotides. It has operations in Singapore, the US, Japan, the UK, and Ireland. Wave Life Sciences is headquartered in Singapore City, Singapore.
Headquarters
Singapore
Address
7 Straits View, #12-00, Marina One East Tower, Singapore City, 018936
Website
www.wavelifesciences.com
No of Employees
287
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
WVE (NASD)
Revenue (2024)
$42.7M
-60.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-110.7%
(2024 vs 2023)
Market Cap*
$1.4B
Net Profit Margin (2024)
XYZ
-434.0%
(2024 vs 2023)
* As of and is in US$
Wave Life Sciences Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| WVE-006: Alpha-1 Antitrypsin Deficiency (AATD) |
| WVE-007: Obesity and Other Metabolic Disorders |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Wave Life Sciences Ltd | Puma Biotechnology Inc | MacroGenics Inc | Allied Life Sciences Pte Ltd | Holos Life Sciences Pte Ltd |
|---|---|---|---|---|---|
| Headquarters | Singapore | United States of America | United States of America | Singapore | Singapore |
| City | Singapore City | Los Angeles | Rockville | Singapore City | Singapore City |
| State/Province | - | California | Maryland | - | - |
| No. of Employees | 287 | 179 | 293 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christian Henry | Chairman | Executive Board | 2017 | 56 |
| Paul B. Bolno, M.D | President; Director; Chief Executive Officer | Executive Board | 2013 | 50 |
| Kyle Moran | Chief Financial Officer | Senior Management | 2014 | 54 |
| Chandra Vargeese, PhD | Head - Platform Discovery Sciences; Chief Technology Officer | Senior Management | 2020 | 63 |
| Christopher Wright, MD, PhD | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer